Impact of Craniopharyngioma on Quality of Life, Morbidity, Mortality, and Long-Term Outcomes

Overview

Childhood-onset craniopharyngioma leads to significant weight gain and hypothalamic obesity, impacting quality of life and increasing mortality risk. Recent findings suggest that setmelanotide may improve outcomes for patients with hypothalamic dysfunction.

Background

Craniopharyngiomas are rare tumors that predominantly affect children and can lead to severe hypothalamic dysfunction. This dysfunction is associated with a range of health issues, including obesity, cognitive impairments, and reduced quality of life. Understanding the long-term outcomes and management strategies for these patients is crucial for improving their overall health and well-being.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Hypothalamic obesity is a common consequence of craniopharyngioma treatment.
• Patients often experience chronic fatigue, excessive daytime sleepiness, and mood disturbances.
• Overall mortality in craniopharyngioma patients is three- to fivefold higher than in the general population.
• Five-year survival rates for pediatric patients range from 83% to 96%.
• Setmelanotide shows promise in improving outcomes for patients with hypothalamic obesity.

Clinical Implications

Management of hypothalamic syndrome remains challenging, with conventional obesity treatments often ineffective. The introduction of setmelanotide may provide a new therapeutic option for improving metabolic and psychosocial outcomes in affected patients.

Conclusion

The findings highlight the complex challenges faced by patients with craniopharyngioma and the potential for new therapies to enhance their quality of life and health outcomes.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Journal of Neuro-Oncology, 2016 -- Cognitive functioning in meningioma patients: a systematic review
3. Journal of Neuro-Oncology, 2010 -- Endocrine, neurological, and visual complications following craniopharyngioma treatment
4. ScienceDirect, 2025 -- Diagnosis and management of children and adult craniopharyngiomas
5. PMC, 2023 -- Diagnostic criteria for acquired hypothalamic obesity
6. Journal of Neuro-Oncology — Long-term Follow-up of Healthcare Use and Expenses in Patients with Intracranial Meningiomas
7. Setmelanotide for the treatment of acquired hypothalamic obesity
8. Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement - ScienceDirect
9. 《儿科中枢神经系统癌症，第2.2025版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南》 - Suppr | 超能文献
10. Diagnostic criteria for acquired hypothalamic obesity – international expert guidance document - PMC
11. Daytime sleepiness and health-related quality of life in patients with childhood-onset craniopharyngioma | Scientific Reports
12. Long-term quality of life and hypothalamic dysfunction after craniopharyngioma - PubMed
13. https://academic.oup.com/jes/article/9/Supplement_1/bvaf149.074/8298875
14. Treatment of Hypothalamic Obesity With GLP-1 Analogs | Endocrine Society